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research is needed to understand how differences in the characteristics of the 
patients treated with PR+T versus PR impact on treatment adherence and 
hospitalization patterns observed.  
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OBJECTIVES: To evaluate hepatitis A (HAV) endemicity in six countries via 
systematic review of published literature. The countries represent varying 
seroprevalence (different stages of the HAV epidemiologic transition), stages of 
vaccine consideration, and face different circumstances that may affect vaccine 
adoption. METHODS: Articles published from 1990 to October 2011 were 
identified through a number of article search engines, including PubMed®. Search 
terms were “Hepatitis A” and [Country]. Reference lists of identified articles were 
reviewed for relevant articles published prior to 1990. A supplementary Internet 
search identified additional information not indexed in the reviewed search 
engines. Articles were excluded if they focused on the biological mechanisms of 
hepatitis A, were non-human studies, vaccine trial results, case studies or 
opinion pieces. RESULTS: A total of 797 articles were identified. After exclusions, 
the number of articles reviewed were: Chile, 33; India, 80; Mexico, 25; Russia, 38; 
South Korea, 75; and Taiwan, 65. India is still considered to have high HAV 
endemicity, while Chile and Mexico are intermediate, and Korea, Russia, and 
Taiwan are low. The timeframe of available data differed greatly by country and 
often region/city within a country, with some regions only having data as recent 
as five (in Mexico, Taiwan) or ten (in Chile, India, Russia) years ago. Data 
supporting the HAV epidemiologic transition varied by country, and it was often 
unclear at which point the country transitioned to a lower endemicity category, 
if at all. Hepatitis A incidence data were sparse for some countries, and recent 
outbreaks were reported in Korea and Taiwan. CONCLUSIONS: Data gaps, 
including determination of the HAV epidemiologic transition, exist to some 
extent in all the countries studied. Filling these data gaps to enhance knowledge 
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OBJECTIVES: Pharmaceutical spending in Brazil represents approximately 11% of 
its total Gross Domestic Product (GDP). Sales of generics represented 17.2% of the 
pharmacy sector by value and 21.3% by volume in 2010, and are expected to grow 
at a higher rate than the overall pharmacy market. This study looks at how the 
increase in generics use, along with reference price controls, may impact access 
to newly approved Community Acquired Pneumonia (CAP) drugs. METHODS: An 
array of published data such as pricing process, current policies, sector-specific 
research articles contributed towards a framework to understand the key factors 
affecting access to CAPs drugs, were gathered. The data then informed a 
telephone survey of national and regional health care stakeholders (N=5). 
RESULTS: Findings show that in Brazil: 1) New CAP products are placed in 1 of 2 
product categories based on comparisons to comparator agents; 2) Category I 
products are considered to be better than the comparator and can charge a 
premium price; 3) The price cannot exceed the lowest price of 9 reference 
countries, which are Australia, Canada, Spain, USA, France, Greece, Italy, New 
Zealand and Portugal; 4) Category II products do not demonstrate a benefit over 
the comparator and the price is based on a cost-minimization analysis; and 5) 
There are no national guidelines for treating CAP. CONCLUSIONS: Drugs used to 
treat CAP are compared to comparator agents based on clinical efficacy and 
overall patient benefit. This will determine placement in a product category that 
will drive pricing. Pharmaceutical companies developing new antibiotics to treat 
CAP must 1) consider launch sequence/timing in reference price countries; 2) 
assess the impact of price based on product category placement; 3) demonstrate 
cost–effectiveness of the drug; and 4) determine whether a new product will 
provide a benefit over comparator agents.  
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OBJECTIVES: Attendance at biannual medical visits has been proposed as a 
minimum U.S. standard for adequate engagement in human immunodeficiency 
virus (HIV) care. The U.S. National HIV Surveillance System collects dates of HIV 
laboratory tests but not medical visits, the current metric for determining if a 
patient is engaged in medical care. Using data from the HIV Outpatient Study 
(HOPS), we analyzed how reported laboratory data correlated with actual 
engagement in care. METHODS: The HOPS is an open prospective study of HIV-
infected patients receiving outpatient care. The dataset included dates for 
laboratory measurements and medical encounters. We included patients with at 
least one HIV laboratory test and one medical visit during 2010-2011. An HIV 
laboratory test was associated with a medical visit if it occurred within 3 weeks 
of the visit. We assessed the predictive value of HIV laboratory tests as a proxy 
for adequate engagement in clinical care, defined as having had ≥2 HIV 
laboratory tests within 1 year where the tests were performed ≥90 days apart. 
RESULTS: A total of 10,301 HIV laboratory tests were recorded from among 2,895 
patients. Most (75%) laboratory tests were measured on the same day as a 
clinical visit; 90% were within ±3 weeks. The prevalence of adequate engagement 
in clinical care in HOPS based on medical visits was 89%. Using HIV laboratory 
tests to measure engagement had sensitivity of 85%, specificity of 87%, and 
positive and negative predictive values of 98% and 42%. Of the 21.4% of persons 
classified as not engaged in care by the proxy measure, 58% were actually 
engaged. CONCLUSIONS: Using ≥2 documented HIV laboratory tests measured 
≥90 days apart reliably classified persons as engaged in care. However, more 
than half of persons not meeting the proxy definition were misclassified as not 
adequately engaged in care.  
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OBJECTIVES: Timely initiation of antifungal therapy in septic or critically ill 
(CrILL) patients with candidemia is crucial, and real-world treatment and 
outcomes data in such patients are limited. We examined treatment patterns 
and outcomes for septic/CrILL inpatients with candidemia. METHODS: This 
retrospective study of electronic health record data from 7/2005-3/2012 used 
Cerner’s Health Facts. Adult inpatients with ≥1 blood culture positive for any 
species of Candidaand sepsis/CrILL were studied. CrILL was defined as ≥1 organ 
system dysfunction plus intensive care unit exposure. Timing of initial 
antifungal therapy relative to the index blood culture draw (BCx), length-of-stay 
following first antifungal order (AF-LOS), mortality, and measures of resource 
utilization were explored using descriptive statistics. Chi-square was used for 
proportional, and t-test for continuous data comparisons. RESULTS: Of 1,288 
candidemia patients with sepsis/CrILL, 266 initiated antifungal therapy prior to 
BCx, 150 within 24h of BCx, 590 after 24h, and 282 received no antifungal 
therapy. The mortality rates were 39.9%, 30.7%, 29.7%, and 51.1%, respectively. 
(P<0.001). Initial antifungal therapies in those treated ≤24h of BCx were: 
fluconazole in 54.0%, echinocandin in 39.3%, other azoles in 3.3%, and 
amphotericin B in 3.3%. In patients treated within 24h after BCx with fluconazole 
(n=81) or echinocandin (n=59), occurrence of bacteremia was high (71% vs. 75%); 
echinocandin patients had a higher mean number of organ system dysfunctions 
than fluconazole patients (1.8 vs. 1.5, P=0.04). In the ≤24h treated groups, AF-LOS 
(fluconazole 20.8, echinocandin 22.1 days; P=0.63) and mortality (fluconazole 
25.9%, echinocandin 32.2%; P=0.42) was similar, as were total charges 
(approximately US$76,000). CONCLUSIONS: A large proportion of inpatients with 
candidemia and sepsis/CrILL failed to receive antifungal therapy within 24h of 
the first positive BCx, with an adverse mortality effect. Nonetheless, patients 
treated within 24h have high mortality and resource utilization.  
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OBJECTIVES: In clinical practice, the taste of liquid pediatric antibiotics may 
contribute to treatment acceptance and compliance. The purpose of this study 
was to analyze treatment patterns and persistence with liquid pediatric 
antibiotics, in a real life setting, using the RAMQ database. METHODS: Selected 
patients were < than 20 years old and were covered by the Quebec provincial 
drug reimbursement program (RAMQ). They were prescribed a liquid pediatric 
antibiotic (branded or generic formulation) during the period from July 2008 to 
April 2011 at least once. The analyses evaluated patients and treatment 
characteristics and patterns in terms of short-term (30 days or less) and long-
term (> than 30 days) repeated use. RESULTS: Data were available for a sample of 
67,727 patients who used an antibiotic of interest. The average age of the study 
population was 4.7 years (SD=3.5) and 89.9% were < than 10 years old. The 
proportion of boys versus girls was similar (51.2% versus 48.8%, respectively). 
Amoxicillin trihydrate and macrolides, clarithromycin and azithromycin were 
most often used (49.3% and 33.0%, respectively). About 55.4% of children received 
more than one antibiotic during the study period. Among children who received 
a second antibiotic, about 22.5% required it within 30 days following treatment 
initiation. In the short-term, the need for a second antibiotic was more frequent 
when cephalosporin was the initial treatment. In the long-term, when the initial 
treatment was amoxicillin or a macrolide, subsequent antibiotics were more 
likely to be the same as the first antibiotic. CONCLUSIONS: Many children will 
require more than one antibiotic treatment during their childhood. Several 
factors may contribute to short-term acceptance and compliance of the initial 
antibiotic, one of which may be taste. The better the acceptance and compliance 
to the initial antibiotic, the more likely the same antibiotic will be used for 
subsequent treatments.  
 
NEUROLOGICAL DISORDERS – Clinical Outcomes Studies 
 
PND1  
COMPARATIVE RISKS OF SEVERE CUTANEOUS REACTIONS, ASEPTIC 
MENINGITIS, AND ORGAN DYSFUNCTION ASSOCIATED WITH ANTIEPILEPTIC 
DRUGS  
Chen P, Teigland C, Parente A, Jones B, Scoggins J, Mehta S, Yang X 
Inovalon Inc., Bowie, MD, USA  
